Citadel Advisors’s Allena Pharmaceuticals ALNA Stock Holding History

Citadel Advisors’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37,613	Closed	-$9K	–	14754
2022 Q1	$9K	Buy	37,613 +7,788	+26%	+$3.23K	﹤0.01%	13396
2021 Q4	$17K	Sell	29,825 -17,150	-37%	-$13.4K	﹤0.01%	13611
2021 Q3	$42K	Sell	46,975 -655	-1%	-$641	﹤0.01%	13460
2021 Q2	$62K	Buy	+47,630	New	+$57.7K	﹤0.01%	13237
2020 Q3	–	Sell	-16,268	Closed	-$26K	–	11002
2020 Q2	$26K	Sell	16,268 -5,134	-24%	-$8.62K	﹤0.01%	9494
2020 Q1	$21K	Buy	21,402 +7,455	+53%	+$14.9K	﹤0.01%	9294
2019 Q4	$38K	Buy	+13,947	New	+$45.8K	﹤0.01%	8822
2019 Q1	–	Sell	-10,970	Closed	-$60K	–	10095
2018 Q4	$60K	Buy	10,970 +194	+2%	+$1.67K	﹤0.01%	8440
2018 Q3	$116K	Buy	+10,776	New	+$118K	﹤0.01%	8517
2018 Q2	–	Sell	-11,265	Closed	-$124K	–	9453
2018 Q1	$124K	Buy	+11,265	New	+$94.1K	﹤0.01%	7636

Other funds holding ALNA

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Citadel Advisors's ALNA Position: Q2 2022 in Review

Citadel Advisors sold out of Allena Pharmaceuticals (ALNA) in Q2 2022, closing a stake of 37,613 shares — an estimated $9K sold.

Citadel Advisors first reported a position in ALNA in Q1 2018 and held it in 10 quarters. The position peaked at $124K in Q1 2018. 25 funds tracked by Wall St. Rank hold ALNA as of Q2 2022.

Citadel Advisors reported no remaining Allena Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 37,613 Allena Pharmaceuticals shares in Q2 2022, an estimated $9K.
Citadel Advisors first reported a position in Allena Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Citadel Advisors's Allena Pharmaceuticals position peaked at $124K in Q1 2018.
25 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.